This trial tests a drug combo of tazemetostat, bendamustine and rituximab to treat cancer. Patients get the drugs on a 28-day cycle for up to 3 cycles.
- Follicular Lymphoma
2 Primary · 3 Secondary · Reporting Duration: 2 years
1 Treatment Group
1 of 1
42 Total Participants · 1 Treatment Group
Primary Treatment: Investigational Group · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 33 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the aggregate figure of participants enrolled in this experiment?
"Affirmative. According to clinicaltrials.gov, this study is still recruiting volunteers since it was first posted on January 26th 2023 and last updated on February 8th 2023. It requires 42 patients at a single research centre." - Anonymous Online Contributor
Are there any vacancies available for participants in this experiment?
"Affirmative. Per the information posted on clinicaltrials.gov, this medical trial has been open for recruitment since January 26th and was last updated on February 8th 2023. The study requires 42 participants to be enrolled from a single site." - Anonymous Online Contributor